Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for advanced malignant solid tumors
ChiCTR1800017537Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Non-hematologic malignancy, sponsored by Chongqing University Cancer Hospital. Primary endpoint: progression-free survival. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR1800017537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017537.